FCMV
NERV icon

Foresite Capital Management VI’s Minerva Neurosciences NERV Stock Holding History

Foresite Capital Management VI’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
+1,986,600
New +$11.4M 2.6% 9

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Foresite Capital Management VI's NERV Position: Q1 2026 in Review

Foresite Capital Management VI opened a new position in Minerva Neurosciences (NERV) in Q1 2026: 1,986,600 shares worth $12M. The stake represents 2.6% of the portfolio and ranks #9 among its holdings.

47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Foresite Capital Management VI held 1,986,600 shares of Minerva Neurosciences worth $12M as of Q1 2026.
  • Minerva Neurosciences was a new Foresite Capital Management VI position in Q1 2026.
  • Minerva Neurosciences made up 2.6% of Foresite Capital Management VI's portfolio in Q1 2026, its #9 holding.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Foresite Capital Management VI's 13F filing for Q1 2026, filed 15 May 2026.